Pfizer advances AI-driven procurement to unlock efficiency and compliance in global supply chain

Pfizer is integrating artificial intelligence into its procurement processes across its global operations, focusing on automation, compliance, and measurable ROI to streamline workflows and enhance risk management.

When Scott Whelan, senior director, source-to-pay at Pfizer, quipped during a recent webcast that a brief technical glitch must have been caused by “talking negatively about AI”, he underscored a theme running through Pfizer’s procurement transformation...

: a mixture of cautious humour and determined pragmatism as the company pushes to turn automation into measurable intelligence.

According to the original report on the webcast, Pfizer’s procurement organisation , at the scale of a business with more than 80,000 employees, operations in 200 countries and some 30 manufacturing sites , is moving quickly to apply artificial intelligence to simplify workflows, improve compliance and deliver clear return on investment. The company generated roughly $63 billion in revenue in 2024 and, the report noted, serves more than a billion people with its products each year; that global reach shapes why procurement projects must show quantifiable financial and operational outcomes that can be explained to a CFO.

Pfizer’s work with ORO Labs was presented as a pragmatic, ROI-driven pilot programme focused on three initial use cases designed to reduce friction and speed decision‑making. The first automates a 26‑step requisition approval process: an AI agent now performs checks on supplier documentation, insurance and compliance attachments under “human‑in‑the‑loop” oversight, with a target of achieving a 90% accuracy rate by early next year, after which human intervention would be significantly reduced. The second use case automates supplier onboarding , long a source of delay despite systems such as SAP Master Data Governance , using real‑time APIs to validate suppliers, verify banking details and enforce compliance. Whelan described the old onboarding experience as “painful” in the webcast. The third creates a “procurement front door” that allows users to describe their need in plain language; the AI interprets intent, decides required workflows and routes tasks to existing platforms such as Ariba or Icertis, giving requesters a simplified experience while preserving procurement control.

These projects sit alongside two broader ambitions flagged in the webcast: embedding supplier risk automation across the procurement lifecycle and consolidating siloed enterprise data into a unified, AI‑accessible data lake. The latter, the report said, involves heavy document extraction , “OCR‑ing the heck out of everything,” in the phrasing used during the event , to standardise information from multiple systems and enable advanced analytics, prompt engineering and model training without continual manual data wrangling.

The initiative with ORO should be read in the context of parallel moves by both organisations. ORO Labs has been steadily adding AI capabilities to its procurement orchestration platform; in June 2025 the company introduced pre‑built AI agents and a no‑code AI Agent Builder intended to let procurement teams design agents to automate tasks such as risk reviews, fraud detection and compliance checks, a development its CEO framed as marrying human and machine intelligence to transform procurement. ORO’s tech has also won industry recognition , it was named Procurement Technology Provider of the Year at the World Procurement Awards in May 2025 , and the vendor has been showcasing agentic orchestration at events such as DPW Amsterdam 2025.

For Pfizer, the procurement push forms part of a wider corporate embrace of AI across research and operations. Earlier in 2025 the company announced or expanded several AI partnerships: in February it began a multi‑year collaboration with Data4Cure to apply knowledge‑graph AI and multi‑omics integration to drug discovery and biomarker work, and in January it expanded an alliance with PostEra to accelerate small‑molecule and antibody‑drug conjugate programmes using PostEra’s Proton platform. Longer‑running ties, such as the 2022 expansion of collaboration with CytoReason, reflect a pattern in which Pfizer combines external AI capabilities with internal priorities.

Industry data and vendor statements suggest why this approach is attractive. Procurement teams face tariff volatility, regulatory complexity and sprawling tech stacks; quick wins that reduce cycle times, mitigate risk and preserve compliance are commercially compelling. Pfizer’s stated requirement that each digital project demonstrate measurable ROI reflects broader procurement governance trends that demand clearer links between automation and financial performance.

That said, the road to intelligent procurement carries familiar caveats. The webcast emphasised human oversight in early deployments, and ORO’s platform updates stress the need to integrate human and machine decision‑making. The pilots will need to prove accuracy, data integrity and regulatory robustness at scale , particularly where supplier risk and cross‑border regulatory context are involved. According to the original report, Pfizer aims to have the three core use cases live within the first half of next year, a timeline that signals both urgency and an appetite for rapid iteration.

Whelan framed the end goal in practical terms during the webcast: procurement should free scientists and business users from the mechanics of buying so they can focus on value‑creating work, while procurement retains visibility and control. For Pfizer, AI is presented not as a buzzword but as “a new way of working” , one intended to align efficiency gains with mission‑critical compliance and risk management as the company scales automation across a complex global supply base.

Source: Noah Wire Services